Download Career/Academic Appointments

Hari Deshpande, MD
CURRICULUM VITAE
Date of revision:
6/28/2016
Name:
Hari A. Deshpande, M.D.
Proposed for Promotion to: Associate Professor of Medicine, Section of Medical
Oncology
Clinician – Educator Track (with Secondary
Appointments in Surgery (Otolaryngology) and School
of Nursing)
Term:
July 1, 2013 – June 30, 2018
School:
Yale University School of Medicine
Reason for Promotion:
Education:
BSc
Medical Microbiology, Leeds University, 1988
MBChB, Leeds, England
Medical School:
Leeds University Medical School, 1991
MBChB, Leeds, England
Career/Academic Appointments:
1991-95
Internship in General Medicine & Surgery, LGI and St. James Hospital
Leeds, England
1992-95
Internal Medicine Resident, Albert Einstein College of Medicine,
Bronx, NY
1995-98
Fellow, Division of Hematology & Oncology, Albert Einstein Montefiore
Medical Center Albert Einstein College of Medicine, Bronx, NY
1998-01
Hematologist & Oncologist, Las Vegas Cancer Center
Las Vegas, NV
2001-04
Hematologist & Oncologist, New London Cancer Center
New London, CT
2004-2013
Assistant Professor of Medicine, Section of Medical Oncology, Yale Cancer
Center, Yale University School of Medicine, New Haven, CT
2013-present Associate Professor of Medicine, Section of Medical Oncology, Yale Cancer
Center, Yale University School of Medicine, New Haven, CT
Secondary Appointment
Yale University School of Medicine, Assistant Professor of Surgery,
Department of Otolaryngology
1
Hari Deshpande, MD
Administrative Positions:
2013-present Vice Chairman, Protocol Review Committee, Section of Medical Oncology,
Yale University School of Medicine, New Haven, CT
2005-13
PCC Tutor
2007-present Medical Oncology Section Representative, Yale Affiliated Hospital Program
Oncology course direction, Physicians Associates Program, Yale University
2005-present Member, Oncology Pharmacy and Therapeutics Committee
2005-present Member, Chemotherapy Process Committee Yale Cancer Center, Yale New
Haven Hospital
2005-09
Associate Medical Director, Medical Oncology Outpatient Clinic
Section of Medical Oncology
2005-06
Quality Assurance Supervisor, Comprehensive Cancer Center,
VA Connecticut Healthcare System
2013-present Vice-Chairman, Protocol Review Committee, Section Medical Oncology,
Yale University School of Medicine, New Haven CT
Board Certification:
Diplomat of the American Board of Internal Medicine, 1995-2015
Diplomat of the American Board of Hematology, 1998-2018
Diplomat of the American Board of Medical Oncology, 1999-2019
Professional Honors and Recognition
International /National/Regional
1995: “Davidoff Teaching Award for Outstanding Teaching of Medical Students,”
Albert Einstein College of Medicine
University:
2015: “The Physician Compassionate Caregiver Award” presented by the Yale Cancer
Center/Smilow Hospital
2011: “David S. Fischer Award for Medical Oncology” Yale Cancer Center
2008: Leonard Tow Humanism in Medicine Award” presented by the Arnold P.
Gold Foundation (nominee), Yale University School of Medicine
Grants/Clinical Trials History:
Current Grants:
None
Current Clinical Trials:
Agency:
I.D.#:
Title:
Saza
HIC: 1404013771
Pilot study to assess the activity of demethylation therapy with HPV positive
compared with HPV negative HNSCC
Role:
P.I.
Percent effort:
2
Hari Deshpande, MD
Total costs for project period:
Project period: 6/4/2014-6/3/2015
Agency:
PSMADC
I.D.#
HIC: 1211011046
Title:
A phase 2 open label Study of PSMA ADC in patients with CRPC.
Role:
PI Yale Site Sub Investigator
Percent Effort: 5%
Total costs for project period:
Project period: 3/11/13-3/11/15
Agency:
SWOG
I.D.#
HIC: 1212011253
Title:
Abiraterone Acetate for PSA nadir greater than 4.
Role:
PI Yale Site sub Investigator
Percent effort: 5%
Total costs for project period:
Project period: 11/19/12- 11/15/23
Agency:
I.D.#
Title:
Lilly/Imclone
HIC: 1211011153
A phase 2 evaluating the safety and efficacy of docetaxel with either IMC
1121B or IMC 18F1 in second line TCC patients.
Role:
PI Yale Site Sub Investigator
Percent effort: 5%
Total costs for project period:
Project period: 3/19/13 – 3/19/15
Agency:
I.D.#
Title:
Oncogenix
HIC: 1211011047
A randomized double blind Phase 2 study comparing gemcitabine and
cisplatin in combination with OGX 427 or placebo in patients with advanced
transitional cell carcinoma..
Role:
PI Yale Site sub Investigator
Percent effort: 5%
Total costs for project period:
Project period: 3/7/13 – 3/20/15
Agency:
I.D.#
Title:
Bobcat
HIC: 0904005035
A phase 3 Randomized, Double-blind, placebo-controlled Study of
Abiraterone, Acetate (CB7630), Plus Prednisone in asyptomatic or mildly
sympotamatic Patients with Metastatic Disease.
Role:
PI Yale Site Principal Investigator
Percent effort: 5%
Total costs for project period:
3
Hari Deshpande, MD
Project period: 7/1/09 – 7/1/15
Agency:
I.D.#:
Title:
ECOG
HIC 8120
Phase III, chemotherapy +/- bevacizumab in treating patients with recurrent or
metastatic head and neck cancer
Role:
P.I.
Percent effort:
Total costs for project period:
Project period:
8/1/2011-6/3/2015
Agency:
I.D.#
Title:
ECOG
HIC: 1103008128
CHAARTED ChemoHormonal Therapy versus Androgen Ablation
Randomized Trial for Extensive Disease Prostate Cancer
Role:
Yale Site Principal Investigator
Percent effort: 5%
Total costs for project period:
Project period: 8/20/11 – 8/25/21
Agency:
I.D. #
Agency:
Title:
Onyx
HIC: 0609008123
Onyx
A Multicenter Phase II Trial of Gemcitabine, Carboplatin and Sorafenib in
Patients with Advanced Metastatic Bladder Cancer
Role:
Yale Site Principal Investigator
Percent effort: 5%
Total costs for project period:
Project period: 2/19/07 – 2/19/15
Agency:
I.D. #
Title:
Hoffman LaRoche
HIC# 1111009271
An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor
RO5185426 in Patients with Metastatic or Unresectable Papillary Thyroid
Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to
Radioactive
Role:
Yale Site Principal Investigator
Percent effort: 5%
Total costs for project period:
Project period: 12/22/11 – 12/22/14
Agency:
I.D.#
Astra Zeneca
0608001747
4
Hari Deshpande, MD
Title: An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled MultiCenter Study to Assess the Efficacy of ZD6474 (ZACTIMATM) versus Placebo in
Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Role:
P.I.
Percent Effort: 5%
Total Costs for project period:
Project period: 9/10/06-9/10/14
Agency:
I.D.#:
Title:
Janssen
1203009937
A Randomized Controlled Study of YONDELIS (Trabectedin) or
Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma
Role:
P.I.
Percent Effort: 10%
Total costs for project period:
Project period: 1/17/13-1/17/15
Agency:
I.D.#:
Title:
Bayer
0906005375
A Double-Blind, Randomized Phase III Study Evaluating the Efficacy
And Safety of Sorafenib Compared to Placebo in Locally Advanced/
Metastatic RAI-Refractory Differentiated Thyroid Cancer (BAY 43-9006)
Role:
P.I.
Percent Effort: 5%
Total costs for project period:
Project period: 6/21/09-12/30/14
Agency:
I.D.#:
Title:
Exelixis
1211011159
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib
(XL184) vs. Prednisone in Metastatic Castration resistant Prostate Cancer
Patients who have Received Prior Docetaxel and Prior Abiraterone or
MDV3100
Role:
P.I.
Percent Effort: 10%
Total costs for project period:
Project period: 10/4/12-10/4/14
Past Grants:
None
Past Clinical Trials:
Agency:
No Sponsor
Title:
Phase I trial of Satraplatin and Abraxane in advanced solid tumors. 2006Role:
Yale Site Principal Investigator
Percent effort:
5
Hari Deshpande, MD
Total costs for project period:
Project period:
Agency:
No Sponsor
Title:
Retrospective study of chemotherapy use in elderly patients 2006
Role:
Yale Site Principal Investigator
Percent effort:
Total costs for project period:
Project period:
Agency:
Title:
Astra Zeneca
Phase III trial of Iressa in 2 doses vs. methotrexate in patients with recurrent
head and neck squamous cell carcinomas (Astra Zeneca sponsored study)
2004-2005 Head and Neck Disease Unit group; Yale Cancer Center
Role:
Yale Site Principal Investigator
Percent effort:
Total costs for project period:
Project period:
Agency:
Title:
ECOG
A Phase III trial of Iressa vs Docetaxel in patients with recurrent Head and
neck squamous cell cancer (ECOG study) 2005
Role: Yale Site Principal Investigator
Percent effort:
Total costs for project period:
Project period
Agency:
Title:
ECOG
Phase II trial of bortezomib with the addition of doxorubicin on progression,
in patients with adenoid cystic carcinoma; (ECOG study) 2005 Head and
Neck Disease Unit group; Yale Cancer Center
Role:
Yale Site Principal Investigator
Percent effort:
Total costs for project period:
Project period
Invited Speaking Engagements, Presentations, Symposia & Workshops Affiliated With
Yale:
2016:
2015:
2015:
2015:
2015:
ASCO Review 2016: “Case Presentation: Genitourinary Cancers” June
Greenwich Subspecialty/Oncology, “GI Cancers: colon pancreas”, Dec.
The 3rd Annual New England Endocrine Tumor Symposium at Yale, “Management
of Advanced Thyroid Cancer”, November
YNHH Department of Food and Nutrition Oncology Symposium, “Ask the Experts
Panel, November
Hematology/Oncology Fellows Summer Lecture Series, “Chemotherapy Toxicities
6
Hari Deshpande, MD
& Supportive Care”, July
2015: Yale PA Program, “Introduction to Oncology”, Sept.
2015: Grand Rounds, St.Mary’s Hospital, “Oncologic Emergencies, September
2015: Tumor Conference, Greenwich Hospital, “Case presentation” September
2015: Yale Hematology/Oncology Core Curriculum Lecture Series, “Head and Neck
Cancers”
2015: Oncology Conference, Bridgeport Hospital, “Head and Neck Cancer”
Therapeutic Grand Rounds, Yale University, “Updates in Sarcoma”
Grand Rounds, St. Mary’s Hospital, “Prostate Cancer Updates”
Yale Physician Associate Program, “Introduction to Oncology”
The New England Endocrine Tumor Symposium at Yale, “New Guidelines in the
Management of Advanced Thyroid Cancer”
2014: Tumor Conference, Greenwich Hospital, “Thyroid”
2014: Schwartz Center Rounds, Yale Cancer Center, “How Do We Get to the End?”
2014: Noon Conference, St. Raphael’s, “Oncologic Emergencies”
2014: Yale Cancer Center Fellowship Summer Seminar Series, “Chemotherapy Toxicities
& Supportive Care”
2014: EMLS Lecture Series, “Oncologic Emergencies”
2014: Internal Medicine Residents, Saint Raphael Campus, “Thyroid Cancer Update”
2014: Grand Rounds, St. Mary’s Hospital, “thyroid cancer”
2014: PA Program, “Testicular Cancer”
2014: PA Program, “Prostate Cancer”
2014: Medical Oncology Fellowship Conference, “Thyroid and Other Endocrine Tumors”
2013: Radiation Oncology Grand Rounds, ‘Updates in the diagnosis and treatment of
Prostate cancer”
2013: Yale Cancer Center Evening Oncology Series: Prostate & urologic Cancers, “Novel
agents for refractory prostate cancer”
2013: PA Program talks: “Introduction to Oncology”; “Prostate Cancer”; Journal Club”;
“Testicular Cancer”
2013: The New England Endocrine Tumor Symposium at Yale: “Novel Targeted Therapies
in Advanced Thyroid Cancer”
2013: Ward Teaching Rounds, Danbury Hospital
2011-12 Medical Grand Rounds lecture – Bridgeport Hospital
2012
Medical Grand Rounds Yale School of Medicine
2012
Urology Grand Rounds Yale
2011-12 Interviewed on Yale Cancer Center Answers (NPR broadcast)
2015:
2015:
2015:
2014:
Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated
with Yale:
2016: CME Conference, University of the West Indies, Kingston, Jamaica, “Updates on
Cancer, Infections, Genomics: From Bench to Clinic”, The University of the
West Indies, Kingston, Jamaica
7
Hari Deshpande, MD
2014: Abstract for AACR annual meeting, San Diego, CA,”An exploratory analysis of
efficacy and safety of abiraterone actate (AA) in black patients (pts) with metastatic
castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx)
2014 American Thyroid Association Meeting, Coronado, CA. Abstract, “Utility of lymph
node dissection for parathyroid carcinoma”
2014 ASCO 2015 GU Cancers Symposium, Orlando FL Abstract, “Phase II trial of
abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a
PSA of more than four following initial androgen deprivation therapy: SWOG
S1014”
2014 Tumor Registrars Association of Connecticut (TRAC) Annual Education Meeting,
New Haven, CT, “HPV Related Head & Neck Cancers and Their Treatments”
2014: St. Luke’s Episcopal Church, New Haven CT Annual Health Series, “Head and Neck
Cancer”
2014: Resident lecture, Griffin Hospital, “Head and Neck Cancer”
2014: Resident lecture, Griffin Hospital, “Prostate Cancer”
2014: VA Healthcare Systems, West Haven CT, house staff conference, “Prostate Cancer”
2014: VA Healthcare Systems, West Haven CT, house staff conference, “Head and Neck
Cancer”
2014: VA Healthcare Systems, Oncology Education Series, “New targets and Precision
Oncology”
2014: American Academy of Professional Coders Chapter Meeting, “Medical Oncology
Coding, Compliance, and Clinical Trials
2013: Grand Rounds, Christiana Health System, Newark, Delaware, “Updates in Prostate
Cancer”
2013: 83rd Annual meeting of the American Thyroid Association, San Juan, Puerto Rico,
“Discussing a treatment option for a rare disease: advanced medullary thyroid
cancer”
Regional Speaking:
None
International Speaking:
None
Professional Services:
Peer Review Groups/Grant Study Sections:
2008-present Connecticut State Medical Society
2007
Grant Reviewer, Oncology Panel, FDA Office of Orphan Products
Development
2003-04
Research Administrator, New London Cancer Center
1998-06
American Society of Hematology
1997-present American Society of Clinical Oncology
2005-present Pre Clinical Clerkship Preceptor for 1st and 2nd Year Yale
8
Hari Deshpande, MD
Medical Students
2007-present Oncology Course Director, Yale PA Program
2006-present Preceptor, Yale APRN Program
2006-present Tutor, Yale Medical School Pre Clinical Clerkship program
Advisory Board:
None
Journal Service:
2014-present Member and Reviewer, Annals of Thyroid Research
2014-present Reviewer, International Journal of Endocrine Oncology
2014-present Reviewer, Future Medicine
Professional Service for Professional Organizations:
2007-present Member, Yale Cancer Center/YNHH Cancer Committee
2006-present Member, YMG Credentials Committee
2005-present Vice-Chairman, Yale Cancer Center Protocol Review Committee
2011-present Member Yale Center Steering Committee
Yale University Services:
Medical School Committees
2014-present Member, Ambulatory Clinic Committee
2011-present Member Yale Center Steering Committee
2007-present Member, Yale Cancer Center/YNHH Cancer Committee
2006-present Member, YMG Credentials Committee
2005-present Member, Yale Cancer Center Protocol Review Committee
2005-present Member, Oncology Pharmacy and Therapeutics Committee, Yale University
School of Medicine, New Haven CT
2005-present Member, Chemotherapy Process Committee Yale Cancer Center, Yale New
Haven Hospital, New Haven CT
2005-present Primary Care Center tutor
Hospital Committees
2015-present Pharmacy & Therapeutics Committee
Public Service:
2015:
Yale Cancer Center Answers radio show, “Head & Neck”, July
2014:
St. Luke’s Episcopal Church, Annual Health Series, “Head and Neck
Cancers”
Bibliography:
Peer-Reviewed Original Research
1. Deshpande HA, Hu XP, Marino P, Jan NA and Wiernik PH. Anticipation in Familial
Plasma Cell Dyscrasias. Br J Hematol 1998 Dec:103(3):696-703 PMID: 9858219.
9
Hari Deshpande, MD
2. Deshpande HA. Dutcher JP. Novik N. Oleksowicz L. Successful treatment of a patient
on adrenal steroid replacement therapy with high-dose bolus interleukin-2 for metastatic
renal cell carcinoma. Cancer Journal 1999; 5: 52-3.
3. Malkhasyan K, Deshpande HA, Adeniran AJ, Colberg JW, Petrylak DP. The use of
serum hCG as a marker of tumor progression and of the response of metastatic urothelial
cancer to systemic chemotherapy. Oncology (Williston Park) 2013; Oct:27(10):
1028,1030. PMID: 24367863 (PubMed in process)
4. Abu-Khalaf, MM, Baumgart MA, Gettinger, SN, Doddamane I, Tuck TP, Hou S, Chen N,
Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande, HA, DiGiovanna, M,
Azodi, Schwartz PE, Harris, L. Phase Ib study of the mammalian target of rapamycin
inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxed in
patients with advanced solid tumors. Cancer 2015 Feb 3 (Epub ahead of print) PMID:
25649370.
Chapters, Books, and Reviews
5. Deshpande, HA, Gettinger SN, Sosa JA-Novel chemotherapy options for advanced
thyroid tumors: small molecules offer great hope. Curr Opin Oncol. 2008 Jan; 20(1) :1924 Review PMID: 18043252
6. Flannigan J, Deshpande H. Gettinger S. Current status of vandetanib (ZD 6473 in the
treatment of non-small cell lung cancer. Biologics, 2010 Set. 13: 4:237-43
PMID: 20859451
7. Deshpande, HA, Gettinger S, Sosa JA-Axitinib: The evidence of its potential in the
treatment of advanced thyroid cancer. Core Evid 2010,Jun 15; 4:43-8 PMID:
20694064
8 Deshpande, H, Roman S, Thumar J, Sosa JA. Vandetamib) ZD6474) in the Treatment
of Medullary Thyroid Cancer. Clinical Med. Insights Oncol. 2011; 5:213-21 Epub.
2011 July 20. PMID 21836817
9 Degrauwe N. Sosa JA, Roman S, Deshpande HA Vandetanib for the treatment of
metastatic medullary thyroid cancer. Clin Med Insights Oncol. 2012 6:243-52 Epub
2012 June 7 PMID: 22723734
10 Deshpande H, Sheth K, Sosa JA, Roman S. Efficacy and tolerability of pharmacotherapy
options for the treatment of medullary thyroid cancer. Clin Med Insights Oncol, 2012;6:
355-62 Epub 2012 Oct 31. PMID: 23133319. PMCID: PMC3489097
11. Deshpande H, Roman S, Sosa JA. New targeted therapies and other advances in the
management of anaplastic thyroid cancer. Curr Opin Oncol. 2013 Jan;25(1):44-9.
PMID: 23159847.
12. Deshpande HA, SN Gettinger SN, and Sosa JANovel chemotherapy options for
advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol
2008;20:19-24 2008 PMID: 18043252
13. Copur MS, Chu E, Harrold LJ, Deshpande HA, and Levy AL. Common Chemotherapy
Regimens in Clinical Practice. In Chu, E (ed), Physician’s Cancer Chemotherapy Drug
Manual 2010, Jones & Bartlett Publishers, Sudbury, MA, page 404
14. Deshpande HA, Copur MS, Harrold LJ, Chu E, and Levy AL. Antiemetic Agents for the
Treatment of Chemotherapy – Induced Nausea and Vomiting. In Chu, E (ed), Physician’s
10
Hari Deshpande, MD
Cancer Chemotherapy Drug Manual 2010, Jones & Bartlett Publishers, Sudbury, MA, p.
515
15. Deshpande HA, Gettinger SN, Sosa JA Targeted therapy for thyroid cancer.
An update review of investigational agents. Current Opinion in Investigational Drugs;
2010; 11 (6) 661-8
16. Triano, LR Deshpande, HA, Gettinger, SN, Sosa JA, Management of patients with
advanced non-small cell lung cancer: current and emerging options. Drugs 2010; 70 (2)
167-79 PMID: 201-08990
17. Deshpande HA, Marler V, Sosa JA. Clinical utility of vandetanib in the treatment of
patients with advanced medullary thyroid cancer. Onco Targets Ther. 2011; 4:209-15.
Epub 2011. Dec. 9 PMID: 22241953
18. Copur MS, Gettinger SN, Goldberg SB, Deshpande HA. Miscellaneous
Chemotherapeutic Agents. In Cancer Principles & Practice of Oncology. Tenth Edition
(DeVita, Hellman, and Rosenberg, eds) Wolters Kluwer, pp. 267-277, 2015.
Practice Guidelines, Standards and Consensus Statements
19. Gettinger, SN, Deshpande HA. Targeted Therapy in Non Small Cell Lung Cancer”,
Advances (Yale Cancer Center) October 2006.
20. Deshpande, HA, “Prostate Cancer Prevention” MD Health Link, Yale New Haven
Hospital April 25th 2005.
Case Reports
21. Tallon de Lara, Paulino, Holt Elizabeth H, Callender Glenda G, Cheng David,
Deshpande HA. Management of papillary thyroid cancer: an overview for the primary
care physician. J Clin Outcomes Management 2014; 21(5) 233-240
22. Jhaveri AP, Bale, A, Lovick N, Zuckerman K, Deshpande HA, Rath K, Schwartz P,
Hofstatter E. The Benefit and Burden of Cancer Screening in Li-Faumeni Syndrome: A
Case Report. Yale J Biol Med. 2015 June 1:181-5. eCollection 2015
11